Download the Infographic Courtesy of TriNetX Experts Bringing a new drug to market is expensive, complex, and slow. Clinical trials are a major bottleneck. $314 million – $4.46 billion: Estimated cost for a new drug1 Up to 85%: Trials experience delays2 Up to $1...
With Robert F. Kennedy Jr. now at the helm of the Department of Health and Human Services (HHS), his recent speech to agency staff marked the beginning of what could be a seismic shift in U.S. healthcare policy. Among his key initiatives: launching investigations into...
Combining disparate data sources to inform clinical trial site selection has long been a complex challenge. Inconsistent site naming, differences in the definition of a site, and a lack of potential patient counts, among other obstacles, have made it difficult for...
Real-world data (RWD) and the real-world evidence (RWE) derived from analysis of the data are a cornerstone of clinical advancements in today’s fast-paced research environment. However, integrating, harmonizing, and leveraging global datasets at scale presents...
The healthcare and clinical research industries are undergoing a seismic shift. Rapid advancements in real-world data (RWD), artificial intelligence (AI), and patient-centric approaches are rewriting the playbook for clinical trials and treatment development. The...
Clinical trials are vital to drug development but often face challenges such as slow patient recruitment, high costs, and suboptimal trial designs. Today, artificial intelligence (AI) and real-world data (RWD) are transforming this process by optimizing trial...
